CoChat

Dual and Selective Actions of Glucocorticoids upon Basal and Stimulated Growth Hormone Release in Man

Burguera, Bartolome, Muruais, Covadonga, Peñalva, Angela, Dieguez, Carlos, Casanueva, Felipe F. · 2008 · Neuroendocrinology

The DOI matches its Crossref record.

Abstract

In humans, corticoids suppress growth and growth hormone (GH) secretion elicited by a variety of stimuli, while in the rat they potentiate both in vivo and in vitro GH release. To further study this problem, growth-hormone-releasing hormone (GHRH) tests were performed in 6 nonobese Cushing’s syndrome patients and 6 controls. The normal GHRH-induced GH secretion was completely abolished in the Cushing’s syndrome group. To study the action of shorter corticoid exposures, 34 volunteers were subjected to four tests each: placebo treatment (control); dexamethasone (Dex) administration 4 mg i.v., 3 h before; Dex 8 mg p.o., 12 h before, and Dex 22 mg p.o. over the 2 days before the pituitary challenge that was always administered at 0 min (12.00 h). In the first test (n = 9), GHRH (1 µg/kg i.v.) induced a GH peak of 14.5 ± 3.8 ng/ml (control) that was potentiated by Dex 4 mg i.v. administered 3 h before (26.4 ± 6.8 ng/ml). On the contrary, longer Dex treatments suppress GHRH-induced GH values (6.0 ± 1.1 ng/ml after Dex 8 mg and 1.8 ± 0.3 ng/ml after Dex 22 mg). Clonidine administration 300 µg p.o. (n = 7) increased GH secretion with an area under the secretory curve (AUC) of 1,274 ± 236 that was potentiated by Dex 4 mg i.v. given 3 h before clonidine (2,380 ± 489) and reduced by Dex 8 mg, the reduction being significant only after 22 mg Dex(595 ± 47). When arginine 30 g was used as pituitary challenge (n = 6), the GH peak (19.1 ± 4.8 ng/ml) and the AUC (1,318 ± 322) were not significanty altered by Dex 4 mg nor by Dex 8 mg, but clearly reduced after pretreatment with Dex 22 mg (11.1 ± 4.6 ng/ml peak; 635 ± 189 AUC). The action of Dex was rather selective for GH secretion, because it did not alter (n = 6) prolactin, luteinizing hormone and follicle-stimulating hormone stimulated by a combined administration of luteinizing-hormone-releasing hormone and thyrotropin-releasing hormone. In this group, thyrotropin was only altered after the higher (22 mg) Dex treatment. These results showed a dual action of Dex on GH release in man. Short-term treatment potentiated basal and GHRH-stimulated GH secretion. The stimulatory action of corticoids becomes an inhibitory one when longer treatments are employed, suggesting, though not proving, to be mediated by somatostatin release from the hypothalamus.

Overview

Integrity signals

Registry

Crossref · 10.1159/000125315

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

See all 114

Metadata

Authors
Burguera, B., Muruais, C., Peñalva, A., Dieguez, C., & Casanueva, F. F.
Venue
Neuroendocrinology
Publisher
S. Karger AG
Published
2008-04-03
Volume
51
Issue
1
Pages
51-58
ISSN
  • 0028-3835 (ISSN-L)
  • 1423-0194
OpenAlex
W1993558710
Cited by
104
References
0
Citations by year
2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2019: 1 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 3
FWCI
2.17
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Neuroendocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
Keywords
glucocorticoids, growth hormone secretion, dexamethasone, Cushing's syndrome, clonidine, arginine stimulation, pituitary stimulation, growth hormone suppression, dose-dependent effects, pituitary-adrenal axis, growth hormone excess, growth hormone resistance
MeSH terms
Adult, Arginine, Clonidine, Cushing Syndrome, Dexamethasone, Female, Humans, Male, Metyrapone, Prolactin, Growth Hormone, Growth Hormone-Releasing Hormone, Thyrotropin, Thyrotropin-Releasing Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual and Selective Actions of Glucocorticoids upon Basal and Stimulated Growth Hormone Release in Man. https://app.cochat.ai/papers/10.1159/000125315
The paper
Burguera, B., Muruais, C., Peñalva, A., Dieguez, C., & Casanueva, F. F. (2008). Dual and Selective Actions of Glucocorticoids upon Basal and Stimulated Growth Hormone Release in Man. Neuroendocrinology. https://doi.org/10.1159/000125315

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.